{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-24-000455","form_type":"8-K","ticker":null,"cik":"0001039466","company_name":"NovAccess Global Inc.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.981129+00:00","generated_at":"2026-06-02T22:49:25.941492+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NovAccess enters $26.5K note with AJB Capital and licenses IDH1 biomarker from Cedars-Sinai","bullets":["Issued $26,500 promissory note to AJB Capital Investments, 12% interest, 10% OID, due Oct 26, 2024.","Issued 2.5M unregistered common shares as commitment fee; granted security interest in all assets including StemVax equity.","Default triggers 18% interest, conversion at discount, and 2x principal penalty.","Obtained exclusive IDH1 biomarker license from Cedars-Sinai for predicting vaccine response in glioblastoma.","Intends to use IDH1 as companion diagnostic for TLR-AD1, an FDA Orphan Drug designated candidate for CNS cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-24-000455","json":"https://secwatch.observer/filing/0001185185-24-000455.json","markdown":"https://secwatch.observer/filing/0001185185-24-000455.md","text":"https://secwatch.observer/filing/0001185185-24-000455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1039466/000118518524000455/0001185185-24-000455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1039466/000118518524000455/novaccess20240501_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:49:25.941492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7c4b5eacbadad97178203303b1f4ad4e20db6a3","claim":"NovAccess Global Inc. incurred convertible notes of $26,500 with AJB Capital Investments, LLC at 12% a year maturing October 26, 2024.","evidence_excerpt":"On April 29, 2024, NovAccess Global Inc. (“NovAccess” or the “company”) entered into a securities purchase agreement (the “SPA”) with AJB Capital Investments, LLC (“AJB”) and issued a promissory note in the principal amount of $26,500 (the “note”) to AJB pursuant to the SPA.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1039466/000118518524000455/0001185185-24-000455-index.htm","confidence":0.98,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$26,500"},{"label":"Counterparty","value":"AJB Capital Investments, LLC"},{"label":"Rate","value":"12% a year"},{"label":"Maturity","value":"October 26, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"33efa7ba878918ecbeac7d12f441a7173ee39d23","claim":"NovAccess Global Inc. entered into securities purchase agreement with AJB Capital Investments, LLC (effective 2024-04-29).","evidence_excerpt":"On April 29, 2024, NovAccess Global Inc. (“NovAccess” or the “company”) entered into a securities purchase agreement (the “SPA”) with AJB Capital Investments, LLC (“AJB”) and issued a promissory note in the principal amount of $26,500 (the “note”) to AJB pursuant to the SPA.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1039466/000118518524000455/0001185185-24-000455-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"AJB Capital Investments, LLC"},{"label":"Effective","value":"2024-04-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}